Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: A controlled laboratory study

Critical Care

Volumn 14, Issue 4, 2010, Pages

  Schouten, Marcel ^a   van't Veer, Cornelis ^a   Roelofs, Joris J T H ^a   Levi, Marcel ^a   van der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; CEFTRIAXONE; FIBRIN DEGRADATION PRODUCT; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN; MYELOPEROXIDASE; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; BLOOD CLOTTING FACTOR 5;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL GROWTH; BLOOD CLOTTING; GENE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; ACTIVATED PROTEIN C RESISTANCE; ANIMAL; BLOOD CLOTTING TEST; FEMALE; GENETICS; HOMOZYGOTE; LUNG; MALE; PATHOLOGY; PHYSIOLOGY; POINT MUTATION;

ACTIVATED PROTEIN C RESISTANCE; ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD COAGULATION TESTS; CEFTRIAXONE; FACTOR V; FEMALE; HOMOZYGOTE; LUNG; MALE; MICE; PNEUMONIA, PNEUMOCOCCAL; POINT MUTATION;

EID: 78651226828     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9213     Document Type: Article

References (30)

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72. 10.1086/511159, 17278083.
2. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SCB, Dhainaut JF. Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study. Crit Care Med 2005, 33:952-961. 10.1097/01.CCM.0000162381.24074.D7, 15891319.
3. Vail GM, Xie YJ, Haney DJ, Barnes CJ. Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without Streptococcus pneumoniae. Infection 2009, 37:358-364. 10.1007/s15010-008-8128-6, 19169631.
4. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000, 31:347-382. 10.1086/313954, 10987697.
5. Schouten M, Wiersinga WJ, Levi M, Van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008, 83:536-545. 10.1189/jlb.0607373, 18032692.
6. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia - Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000, 161:454-462.
7. Rijneveld AW, Weijer S, Bresser P, Florquin S, Vlasuk GP, Rote WE, Spek CA, Reitsma PH, Van der Zee JS, Levi M, Van der Poll T. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006, 34:1725-1730. 10.1097/01.CCM.0000218807.20570.C2, 16625114.
8. Choi G, Hofstra JJH, Roelofs JJTH, Rijneveld AW, Bresser P, Van der Zee JS, Florquin S, Van der Poll T, Levi M, Schultz MJ. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 2008, 36:204-210. 10.1097/01.CCM.0000292012.87482.F4, 18090375.
9. Choi G, Schultz MJ, Levi M, Van der Poll T, Millo JL, Garrard CS. Protein C in pneumonia. Thorax 2005, 60:705-706. 10.1136/thx.2004.037341, 1747500, 16061717.
10. Rijneveld AW, Florquin S, Bresser P, Levi M, De Waard V, Lijnen R, Van der Zee JS, Speelman P, Carmeliet P, Van der Poll T. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003, 102:934-939. 10.1182/blood-2003-01-0227, 12702502.
11. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, Deronde H, Vandervelden PA, Reitsma PH. Mutation in blood-coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-67. 10.1038/369064a0, 8164741.
12. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995, 85:1504-1508.
13. Majerus PW. Human genetics - Bad blood by mutation. Nature 1994, 369:14-15. 10.1038/369014a0, 8164730.
14. Gopel W, Gortner L, Kohlmann T, Schultz C, Moller J. Low prevalence of large intraventricular haemorrhage in very low birthweight infants carrying the factor V Leiden or prothrombin G20210A mutation. Acta Paediatr 2001, 90:1021-1024. 10.1111/j.1651-2227.2001.tb01358.x, 11683190.
15. Gopel W, Ludwig M, Junge AK, Kohlmann T, Diedrich K, Moller J. Selection pressure for the factor V Leiden mutation and embryo implantation. Lancet 2001, 358:1238-1239. 10.1016/S0140-6736(01)06354-1, 11675065.
16. Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut JF. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003, 102:3085-3092. 10.1182/blood-2003-06-1789, 12869495.
17. Hofstra JJ, Schouten M, Levi M. Thrombophilia and outcome in severe infection and sepsis. Semin Thromb Hemost 2007, 33:604-609. 10.1055/s-2007-985757, 17768693.
18. Brüggemann LW, Schoenmakers SH, Groot AP, Reitsma PH, Spek CA. Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med 2006, 34:2201-2206. 10.1097/01.CCM.0000228918.30931.E8, 16775574.
19. Sun H, Wang X, Degen JL, Ginsburg D. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 2008, 113:1358-1364. 10.1182/blood-2008-07-170506, 2637198, 19056689.
20. Cui J, Eitzman DT, Westrick RJ, Christie PD, Xu ZJ, Yang AY, Purkayastha AA, Yang TL, Metz AL, Gallagher KP, Tyson JA, Rosenberg RD, Ginsburg D. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 2000, 96:4222-4226.
21. Knapp S, Wieland CW, Van 't Veer C, Takeuchi O, Akira S, Florquin S, Van der Poll T. Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 2004, 172:3132-3138.
22. Elms MJ, Bundesen PG, Rowbury D, Goodall S, Wakeham N, Rowell JA, Hillyard CJ, Rylatt DB. Automated determination of cross-linked fibrin derivatives in plasma. Blood Coagul Fibrinolysis 1993, 4:159-164.
23. Verheijen JH, Wijngaards G, Kluft C, Chang G, Mullaart E, Preston FE. A sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator - Its application for measurements in plasma. Haemostasis 1982, 12:62-62.
24. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984, 51:392-395.
25. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, Van der Poll T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002, 168:3507-3511.
26. Knapp S, Wieland CW, Florquin S, Pantophlet R, Dijkshoorn L, Tshimbalanga N, Akira S, Van der Poll T. Differential roles of CD14 and Toll-like receptors 4 and 2 in murine Acinetobacter pneumonia. Am J Respir Crit Care Med 2006, 173:122-129. 10.1164/rccm.200505-730OC, 16210672.
27. Weijer S, Schoenmakers SH, Florquin S, Levi M, Vlasuk GP, Rote WE, Reitsma PH, Spek CA, Van der Poll T. Inhibition of the tissue factor/factor VIIa pathway does not influence the inflammatory or antibacterial response to abdominal sepsis induced by Escherichia coli in mice. J Infect Dis 2004, 189:2308-2317. 10.1086/421031, 15181580.
28. Koster T, Rosendaal FR, Deronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C - Leiden Thrombophilia Study. Lancet 1993, 342:1503-1506. 10.1016/S0140-6736(05)80081-9, 7902898.
29. Russell JA. Genetics of coagulation factors in acute lung injury. Crit Care Med 2003, 31:S243-S247. 10.1097/01.CCM.0000057870.61079.3E, 12682447.
30. Lee SY, Chang SK, Lee IH, Kim YM, Chung SI. Depletion of plasma factor XIII prevents disseminated intravascular coagulation-induced organ damage. Thromb Haemost 2001, 85:464-469.